Global Bioresorbable Coronary Stents Market Size Study, by Material (Polymer, Metal), Drug (Sirolimus, Novalimus), End Use (Outpatient, Inpatient Facilities), and Regional Forecasts 2022-2032

Global Bioresorbable Coronary Stents Market Size Study, by Material (Polymer, Metal), Drug (Sirolimus, Novalimus), End Use (Outpatient, Inpatient Facilities), and Regional Forecasts 2022-2032

The Global Bioresorbable Coronary Stents Market, valued at approximately USD 158.12 million in 2023, is poised to grow steadily at a CAGR of 4.10% over the forecast period 2024-2032. These innovative stents, made from bioresorbable materials, dissolve over time, reducing complications associated with permanent implants. Their capacity to restore normal blood flow in coronary arteries while eliminating the long-term presence of foreign materials underscores their importance in cardiovascular interventions.

The market's expansion is fueled by increasing prevalence of cardiovascular diseases globally and a growing preference for minimally invasive treatments. Bioresorbable stents, with advancements in polymer and metal technologies, are meeting the clinical demand for safer, more effective alternatives to conventional stents. Sirolimus and Novalimus drug coatings further enhance stent performance by minimizing restenosis and inflammation post-implantation. The steady shift toward outpatient facilities for procedures is also bolstering market dynamics by offering cost-effective and patient-friendly solutions.

While high costs and stringent regulatory approvals remain challenges, significant research and development efforts are underway to address these concerns. Advancements in material science and clinical trials demonstrating long-term efficacy and safety are driving broader acceptance among healthcare professionals and patients. Emerging markets in Asia-Pacific and Latin America, with rising healthcare investments and awareness, represent untapped opportunities for the bioresorbable coronary stents industry.

Regionally, North America dominates the market owing to its advanced healthcare infrastructure, strong focus on innovation, and high incidence of cardiovascular diseases. Europe closely follows, driven by supportive government policies and well-established cardiac care facilities. The Asia-Pacific region, with its burgeoning economies and increasing focus on advanced medical devices, is expected to exhibit the fastest growth over the forecast period.

Major market players included in this report are:
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic Plc
• Terumo Corporation
• Biotronik SE & Co. KG
• Meril Life Sciences Pvt. Ltd.
• Elixir Medical Corporation
• OrbusNeich
• Lepu Medical Technology (Beijing) Co., Ltd.
• Amaranth Medical, Inc.
• Reva Medical, Inc.
• Kyoto Medical Planning Co., Ltd.
• C.R. Bard, Inc.
• Stentys SA
• SMT (Sahajanand Medical Technologies)

The detailed segments and sub-segment of the market are explained below:

By Material:
• Polymer
• Metal

By Drug:
• Sirolimus
• Novalimus

By End Use:
• Outpatient
• Inpatient Facilities

By Region:

North America:
• U.S.
• Canada

Europe:
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific:
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America:
• Brazil
• Mexico

Middle East & Africa:
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market estimates and forecasts spanning 2022-2032.
• Annualized revenues with detailed regional and segment analysis.
• Insights into critical market drivers, challenges, and opportunities.
• Profiles of leading market players and analysis of key strategies.
• Regional and global trends shaping the future of bioresorbable coronary stents.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.